Navigation Links
Use Anemia Drugs for Cancer Patients With Caution, Experts Say
Date:10/26/2010

TUESDAY, Oct. 26 (HealthDay News) -- Physicians need to use caution when giving a class of drugs called erythropoiesis-stimulating agents (ESAs) to cancer patients who have anemia caused by chemotherapy, according to new medical guidelines.

And with rare exceptions, ESAs should not be given to cancer patients who are not receiving chemotherapy, according to joint guidelines issued by the American Society of Hematology and the American Society of Clinical Oncology.

ESAs (marketed as Procrit, Epogen and Aranesp) stimulate the bone marrow to produce more red blood cells but are associated with shorter survival and increased risk of blood clots and tumor progression, the guidelines noted.

However, ESAs reduce the need for red blood cell transfusions, which carry a risk of serious infection and adverse reactions in the immune system.

The guidelines offer specific recommendations on the use of ESAs. Among them:

  • ESAs should not be given to cancer patients who are not receiving chemotherapy, except for those with myelodysplastic syndrome (MDS).
  • Doctors should discuss individual risks and benefits of ESAs and blood transfusion with patients before therapy. This shared decision-making is critical.

"This updated guideline offers clinicians the latest synthesis of the medical evidence surrounding the use of ESAs in patients with cancer, including appropriate cautions where evidence is lacking or where risks may outweigh the use of ESAs," guideline panel co-chair Dr. J. Douglas Rizzo, professor of medicine at the Medical College of Wisconsin, said in an American Society of Hematology news release.

"These guidelines touch on almost all aspects of the use of ESAs in patients with cancer and MDS, as well as secondary issues, such as the role of iron supplementation," Dr. Samuel Silver, a member of the ASH Committee on Practice and a professor of internal medicine at the University of Michigan, added in the news release.

The updated guidelines appear online Oct. 25 ahead of print in the Nov. 18 issue of Blood and the Nov. 20 issue of the Journal of Clinical Oncology.

More information

The U.S. Food and Drug Administration has more about ESAs.

-- Robert Preidt

SOURCE: American Society of Hematology, news release, Oct. 25, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Advisers Back Anemia Drugs for Kidney Patients
2. Anemia Drugs Could Pose Threat to Some Kidney Patients
3. Stroke prevention study in children with sickle cell anemia, iron overload stopped early
4. OHSU joins forces with UO, Harvard to accelerate Fanconi anemia research
5. Anemia Drugs Hold Dangers for Kidney Patients
6. Anemia Harder to Treat in Black Children With Kidney Disease
7. Anemia tougher to tackle in black children with kidney disease
8. For Some on Dialysis, Anemia Drugs Pose Risks
9. FDA Tightens Controls on Anemia Drugs
10. FDA Calls for New Warnings on Some Prostate Cancer Drugs
11. Penn study gives hope for new class of Alzheimers disease drugs
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Use Anemia Drugs for Cancer Patients With Caution, Experts Say 
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... Beach, CA (PRWEB) , ... June 25, 2016 , ... ... UCLA with Magna Cum Laude and his M.D from the David Geffen School of ... Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at the ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: